What is DCTH's market cap?

$499.66M, based on the Nov 3 close of $14.40.

What is DCTH's P/E ratio?

939.2× trailing-twelve-month earnings of $532K.

Does Delcath Systems pay a dividend?

No regular cash dividend has been paid in the last year.

How much of DCTH is sold short?

1.9M shares, 7.1% of float, as of Oct 15, 2026.

What sector is DCTH in?

Healthcare, in the Surgical Instruments industry.

NASDAQ · DCTHHealthcareSurgical Instruments

Delcath Systems Inc (DCTH)

$14.40+0.77%

Close Nov 3, 2026 · split-adjusted

Nov 3, 2026$14.40▲ 51.26% in range

Nov 3, 2025Low $8.19 · High $17.36Nov 3, 2026

What changed · written from our data

As of Nov 3, 2026

Delcath Systems closed at $14.40 on Nov 3, up 0.77%, 17.1% below its 52-week closing high. Volume of 386.8K shares was 1.33× its 20-day average (above normal).

Split-adjusted performance: -9.3% over one month, +24.9% over six months, +46.5% over one year.

In the quarter ended Jun 30, 2026, revenue was $29.13M, up 20.6% from a year earlier, with a net margin of 9.2%.

Short interest was 1.9M shares at the Oct 15 settlement, down 3.3% from the prior report (7.1% of float, 6.2 days to cover).

Market cap$499.7M34.7M shares

Revenue · quarter$29.1M+20.6% YoY

Diluted EPS$0.070.0% YoY

P/E · TTM939.2×P/S 5.2×

Net margin9.2%Gross 89.8%

Dividend yieldNone

52-week range8.19 – 17.36−17.1% from high

Volume386.8K1.33× 20-day avg

Volatility · 60d32.9%Annualised

Short % of float7.1%6.2 days to cover

Net cash$95.9MCash $95.9M

Next earnings—Not scheduled

Split-adjusted performance

1W −2.4%1M −9.3%3M +14.0%6M +24.9%YTD +42.6%1Y +46.5%3Y +339.0%5Y +37.9%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Surgical Instruments

Percentile among 110 companies (100 = best)

6-month momentum74

Revenue growth79

Net margin75

Value (low P/E)0

Size62

Industry medians: 6-month return −9.7%, revenue growth +8.9%, net margin −8.2%, P/E 28.1×.

Short interest

Details →

Shares short1.9M−3.3% vs prior

Days to cover6.2Settled Oct 15

% of float7.1%

Short vol. 10d45.4%of daily volume

Closest peers by size in Surgical Instruments

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
DCTHDelcath Systems	$14.40	+0.77%	+24.9%	+20.6%	9.2%	939.2	$499.7M
ANGOAngioDynamics	$11.73	−0.26%	+7.0%	+6.9%	−8.8%	—	$493.3M	Compare
SGHTSight Sciences	$9.42	+2.95%	+117.6%	+19.5%	−19.0%	—	$518.9M	Compare
MDXGMiMedx Group	$3.25	−0.91%	−10.7%	−45.2%	−13.9%	—	$474.3M	Compare
RCELAvita Medical	$15.33	−0.52%	+261.6%	+17.8%	−35.3%	—	$474.1M	Compare
CERSCerus	$2.34	−0.85%	−9.7%	+6.3%	−0.9%	—	$471.6M	Compare
SSIISS Innovations International	$2.33	+0.87%	−40.3%	+39.4%	−19.1%	—	$467.1M	Compare
TCMDTactile Systems Technology	$24.78	+8.35%	+3.0%	+7.1%	7.8%	23.6	$561.3M	Compare
NPCENeuropace	$12.31	−0.24%	−27.8%	+17.1%	−27.2%	—	$422.5M	Compare

News about Delcath Systems

All news →

No recent articles focused on Delcath Systems. 1 articles mention it in passing.

Quick answers

What does Delcath Systems do?: Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers.
What is DCTH's market cap?: $499.66M, based on the Nov 3 close of $14.40.
What is DCTH's P/E ratio?: 939.2× trailing-twelve-month earnings of $532K.
Does Delcath Systems pay a dividend?: No regular cash dividend has been paid in the last year.
How much of DCTH is sold short?: 1.9M shares, 7.1% of float, as of Oct 15, 2026.
What sector is DCTH in?: Healthcare, in the Surgical Instruments industry.

About Delcath Systems

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

HQ: Queensbury, NY156 employeesListed Oct 19, 2000delcath.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology